• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Drug Development - Articles and news items

How the implementation of Exalt™ for evaporative crystallisation studies improves stability and controlled delivery in drug development.

Supplier news / 12 July 2016 / Biopharma Group

Polymorph screening is an important stage of drug development. The aim is to identify the different crystalline structures or polymorphs that a drug may appropriate…

Coulter Partners

Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star

Supplier news / 6 April 2016 / Coulter Partners

Coulter Partners has placed Dr Neil Brewis as Chief Scientific Officer and Michael Davies as VP Protein Science at F-star…

Future proofing - Part 2. PAT – Real Time Release Testing of Tablets

Future proofing – Part 2. PAT – Real time release testing of tablets

Supplier news / 4 April 2016 / Charles Ischi AG | Kraemer Elektronik

What requirements need to be met by a tablet testing system to guarantee a successful product release?

DiscoverX launches KILR™ assay platform for use in cancer immunotherapy drug development

Supplier news / 30 March 2016 / DiscoverX Corporation

DiscoverX Corporation has launched the KILR Retroparticles product line, providing scientists complete flexibility to develop a simple cytotoxicity assay in almost any cell line…

Future proofing - Part 1. Modularity and flexibility New LAB.line Tablet Hardness Testers

Future proofing – Part 1. Modularity and flexibility – New LAB.line tablet hardness testers

Supplier news / 29 February 2016 / Arwid Ischi, Charles Ischi AG | Kraemer Elektronik

What requirements need to be met by a tablet testing system to guarantee a successful product release? Is it dependable upon the testing system’s quality, speed, technology, flexibility or safety? Kraemer and Ischi explain…

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

High Pressure Homogenisation & the next generation of drug delivery: Liposomes

Supplier news / 24 February 2016 / Biopharma Group

Liposomes are valued delivery vehicles for potent and efficacious active pharmaceuticals…

inABLE® technology helps unlock the secrets of cyclic peptides

inABLE® technology helps unlock the secrets of cyclic peptides

Supplier news / 17 February 2016 / Ingenza Laboratory

Ingenza is using its proprietary inABLE® technology to help develop a robust, versatile platform for the production of cyclic peptides for therapeutic use…

Quotient Clinical

Quotient Clinical celebrates its 100th RapidFACT® program

Supplier news / 11 February 2016 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has completed its 100th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the growth of this service, which addresses drug R&D productivity issues…

Quotient Clinical

Quotient Clinical expands its formulation development services with the acquisition of Co-Formulate

Supplier news / 16 December 2015 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited…

Quotient Clinical’s Chief Scientific Officer awarded honorary professorship at the University of Nottingham

Supplier news / 12 August 2015 / Quotient Clinical

Quotient Clinical, the Translational Pharmaceutics® Company, has announced that Dr Peter Scholes, its Chief Scientific Officer, has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham…

Mayor of London considers £10bn ‘megafund’ as option to boost drug development

Industry news / 25 June 2015 / Victoria White

Plans to create a £10bn megafund that would make it easier for drug development will be discussed at a conference hosted by the Mayor of London’s Office…

Quotient Clinical

Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics

Supplier news / 10 June 2015 / kdm communications

Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated…

 

Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +